**Please note that we are no longer taking FLQ cases**
Fluoroquinolones (FLQs) are a popular class of broad spectrum antibiotic drugs that have been proven to carry a significant risk of causing nerve damage in the hands, feet, arms or legs. If you or a loved one have been diagnosed with peripheral neuropathy after taking a FLQ drug such as Cipro, Levaquin, Avelox, Noroxin, Floxin or Factive, you may be eligible for compensation from the drug manufacturer.
Lawsuits are alleging that the drug manufacturer failed to warn consumers and the medical community about the potential side effect of permanent peripheral neuropathy.
May, 2016 – The FDA announced a required label change for the popular class of antibiotics called fluoroquinolones (FLQs) after an internal safety review found the drug class to be associated with “disabling and potentially permanent, serious side effects that can occur together” when used by tablet, capsules, or injection (also known as systemic treatments).
Patients were warned to contact their healthcare provider immediately with symptoms such as “tendon, joint and muscle pain, a “pins and needles” tingling or pricking sensation, confusion, and hallucinations.” Health care providers were warned to stop systemic FLQ treatments immediately in cases where a patient reports such symptoms and recommended that they “switch to a non-fluoroquinolone antibacterial drug to complete the patient’s treatment course.”
An internal FDA safety review found the drug class to be associated with “disabling and potentially permanent, serious side effects.”
Further, the FDA specifically addressed patients with acute sinusitis, acute bronchitis and uncomplicated urinary tract infections to first seek other treatments options when available and to reserve FLQ use only when alternative treatments are not available for patients suffering these conditions.
In addition to this label change and public safety announcement, Medication Guides are also to be updated.
The FDA is continuing to investigate potential safety issues with all fluoroquinolone antibacterial drugs and encourages both patients and health care providers to report side effects involving the drugs.
About the Lawsuit
Patients Report Long-Lasting Peripheral Neuropathy
In 2003, after numerous reports of patients developing symptoms of long-lasting peripheral neuropathy, the FDA began investigating the association between FLQs and peripheral neuropathy. It has since been proven that FLQs carry a significant risk of causing nerve damage in the hands, feet, arms or legs.
Often, fluoroquinolones (FLQs) are an antibiotic used to treat the following medical issues:
- Bacterial bronchitis
- Urinary tract infections
- Septicemia and intra-abdominal infections
- Joint and bone infections
- Soft tissue and skin infections
- Typhoid fever
- Bacterial gastroenteritis
- Urethral and gynecological infections
- Pelvic inflammation
- and more
Peripheral neuropathy occurs as a result of damage to the peripheral nervous system, which sends information from your brain and spinal cord to the rest of your body, usually causing weakness, numbness, and stabbing or burning pain. Symptoms can develop almost immediately after taking FLQs.
Current FLQs available in the United States include Cipro (ciprofloxacin); Factive (gemifloxacin); Levaquin, Quixin, Iquix (levofloxacin); Vigamox, Avelox, Moxeza (moxifloxican); Noroxin (norfloxican); and Floxin, Ocuflox (ofloxican).
As a result of a FDA investigation in 2003, the manufacturers were required to update their warning labels to properly inform consumers of the potential risk to develop peripheral neuropathy. The ensuing warning label warned of a “rare” correlation between the FLQs drug and the development of peripheral neuropathy.
In 2015, a FDA advisory panel discussed the risks and benefits of FLQs continued and systematic use to treat bacterial infections. The result was again to issue stronger labels warning consumers of the risk of side effects, most notably permanent peripheral neuropathy.
During the FDA advisory panel, an executive from Johnson & Johnson, manufacturer of the FLQ Levaquin, testified that FLQs can indeed cause peripheral neuropathy.
During the FDA advisory panel, an executive from Johnson & Johnson, manufacturer of the FLQ Levaquin, testified that FLQs can indeed cause peripheral neuropathy. With federal knowledge of such a relationship dating back to 2003 and the manufacturer’s continued aversion in regards to warning the general public of such a correlation, it is clear that many of these unfortunate instances of peripheral neuropathy could have been avoided. Unfortunately, it’s too late for thousands of victims who have used FLQ’s to treat infections and now suffer from permanent peripheral neuropathy.
Do I Have A Case?
Sanders Phillips Grossman is currently accepting cases across the United States and Puerto Rico from people who have been diagnosed with peripheral neuropathy after taking certain FLQ antibiotics.
Did you or a loved one experience nerve damage after taking a FLQ antibiotic drug such as Cipro, Levaquin, Avelox, Noroxin, Floxin or Factiv? If so, you may be eligible for compensation. Symptoms may include:
- Parenthesia (nerve tingling, prickling, or burning)
- Pain that is shooting or stabbing
- Numbness or weakness that starts in the fingertips or toes before spreading
- Extreme touch sensitivity
- Problems feeling temperatures, textures, or body position
- Decreased muscle coordination
- Problems walking
- Organ damage
- and more
Unfortunately, we will be unable to assist with a claim if you have also been diagnosed with diabetes, fibromyalgia, COPD, Chrones Disease, or if you have had chemotherapy.
What Will An Attorney Cost Me?
We represent our clients on a contingency fee basis. This means that you pay no attorney fees until we win your claim. If we are unable to successfully resolve your claim, you are not obligated to pay attorneys’ fees.